Tissue ExpansionNCT04781907
Patient Performed Tissue Expansion for Two-stage Alloplastic Breast Reconstruction
A study testing Tissue Expansion in people with Tissue Expansion and Breast Reconstruction, run by University of Wisconsin, Madison at 1 site in United States.
Trial summary
This study is designed to evaluate the feasibility and safety of patient performed tissue expansions in two-stage alloplastic breast reconstruction with tissue expanders. The investigators hypothesize that a motivated patient who learns and demonstrates proper technique can safely perform tissue expansions at home… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Tissue Expansion, Breast Reconstruction
- What is being tested?
- Tissue Expansion
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2024to Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Undergoing two stage bilateral alloplastic breast reconstruction with tissue expander (either immediate or delayed)
- Able and willing to present for clinic visits every 1-2 weeks per tissue expansion protocol
- Physical, perceptual and cognitive capacity to understand, learn, perform and manage at-home expansions
- Provision of signed and dated informed consent form
Who cannot join
- Failure to demonstrate proper tissue expander saline infiltration technique after two teachings and observations by clinic staff
- Tissue integrity unsuitable for tissue expansion (compromised vascularity, history of compromised wound healing, mastectomy skin flaps of questionable viability, excessively tight skin envelope)
- Residual gross tumor at intended expansion site
- Current or prior infection at intended expansion site
- Clinically significant fibrosis caused by previous irradiation or planned radiation therapy at intended expansion site during time expander is implanted
- History of failed tissue expansion/breast implant reconstruction
Show all 12Show fewer
- Concomitant medications that may place subject at increased risk of complications (adjuvant chemotherapy, therapeutic anticoagulation, steroids, immunosuppressants)
- Current tobacco smoker
- Comorbid condition that may place subject at increased risk of complications (severe collagen vascular disease, poorly managed diabetes, BMI > 35
- History of psychological condition, drug or alcohol misuse that may interfere with their ability to perform home expansions safely
- Participating in concurrent investigational drug or device study
- Pregnant women
Trial locations and contacts
1 site in 1 country.
About this study
This study is designed to evaluate the feasibility and safety of patient performed tissue expansions in two-stage alloplastic breast reconstruction with tissue expanders. The investigators hypothesize that a motivated patient who learns and demonstrates proper technique can safely perform tissue expansions at home, with no increase in complications or problems with reconstruction. 30 participants will be recruited for this study, 10 into a Home Expansion Group, and 20 into a Control Group.
Read the detailed description
Two-stage tissue expander-to-implant reconstruction is the most common technique for breast reconstruction in the United States. Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants. The current clinical standard of care entails an initial surgery for the placement of tissue expander device either in front or behind of the pectoralis muscle following a mastectomy. After an interval of a few weeks to allow surgical wound healing, the patient will make serial office visits (usually weekly) where the plastic surgeon or other clinical staff will inject the device with a bolus of saline. A probe is used to find the magnetic port embedded in the expander, which is then accessed with a sterile butterfly needle connected to a large syringe filled with saline. The serial injections continue until the tissue expander(s) have reached the desired size. The patient then undergoes a second surgery about 4-6 weeks after the last injection, to exchange the tissue expander with a breast implant.
The tissue expansion process can be inconvenient for the patient, due to the time and cost associated with travel and coordination of frequent office visits. The office visits for tissue expander injections ultimately result with multiple additional encounters with a healthcare facility, which may be of concern to patients, in light of the COVID-19 pandemic.
The saline tissue expander with internal filling port is still the clinical gold standard device for alloplastic breast reconstruction. But the safety, time benefits and healthcare utilization and cost savings of home inflation - as shown in studies using external filling port tissue expanders and carbon dioxide-filled tissue expanders - suggests that patient performed tissue expansions may also be feasible with conventional saline tissue expanders. This would obviate multiple outpatient visits usually required for saline injections. Eliminating the need for saline injection clinic visits would benefit both the clinician and patient/families by reducing financial and time burdens, and limit potential exposures to COVID-19.
Study Design:
Ten women age 18 or above who met the inclusion and exclusion criteria below will be recruited and enrolled in the study. Study participants will be recruited from the principal investigator's clinic. Surgical technique and timing for initiation of expansion and implant exchange will be performed according to the principal investigator's usual protocol with saline tissue expanders. At the first expansion clinic visit, the saline injection will be performed by clinic staff, as per usual protocol. Clinic staff will provide teaching on the saline injection technique during this visit. At the second and third clinic visit, the participant will perform the saline injection under supervision by clinic staff in the right breast, the left breast will be expanded by the clinic staff. Starting the fourth expansion, participants will perform expansion in right breast prior to their clinic visit and left breast will be expanded by clinic staff. Thus participants will still be seen in person on a regular basis as per usual clinical protocol. If after the second and third visit the participant is unable to demonstrate ability and comfort to perform expansions on her own after the third clinic visit, she will be excluded from the study. Participants will be provided instructional materials and all supplies necessary to perform expansions at home. After the tissue expanders have been fully expanded, the participant will proceed to undergo the principal investigator's usual protocol of exchange to breast implants.
If at any time the participant has problem with home expansion or no longer wants to be part of the study, she can leave the study and receive all expansions in the clinic per usual protocol.
Objectives:
- 1. Evaluate overall treatment success in undergoing alloplastic breast reconstruction
- 2. Evaluate profile and rate of complications in patients performing tissue expansions at home
- 3. Compare treatment success and complication profile/rate of right (patient performed tissue expansion) and left (clinic performed tissue expansion) breast
- 4. Compare treatment success and complication profile/rate of patients who perform some tissue expansions at home vs patients who have all tissue expansions performed by clinical staff
- 5. Evaluate patient's satisfaction in experience of learning and performing expansions at home
- Conditions
- Tissue Expansion, Breast Reconstruction
- Being tested
- Tissue Expansion
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tissue ExpansionProcedure or surgery
Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
| Study group | Role | What they receive |
|---|---|---|
| Home Expansion Group | Experimental | Participants in home expansion group will perform the saline injection for their right tissue expander under clinic staff supervision on their 2nd and 3rd expansion. Beginning their 4th expansion, participants will perform saline injection at home prior to their regularly scheduled clinic visit. Receives: Procedure: Tissue Expansion |
| Control Group | No intervention | Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent of Participants who had their breast tissue expanders successfully exchanged from expander to implant
Clinically, the tissue expander is only temporary and the main goal is to get patient to their permanent breast implant
Measured: up to 6 months
Incidence of Adverse Events
Adverse events including - wound dehiscence, seroma, hematoma, extrusion, capsular contracture
Measured: up to 6 months
Secondary outcomes (2)
Number of Right and Left breast tissue expanders successfully exchanged from expander to implant
Participants serve as internal control, with the right breast being expanded by self and left breast being expanded by clinical staff per usual protocol.
Measured: up to 6 months
Incidence of Adverse Events in Left vs Right Breast Tissue Expansion
Participants serve as internal control, with the right breast being expanded by self and left breast being expanded by clinical staff per usual protocol.
Measured: up to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2021
- Study startJun 2024 (estimated)
- Primary completionJun 2025 (estimated)
- Study completionJun 2025 (estimated)
Why it stopped: Change in Research Priorities
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tissue ExpansionStudies of the same condition, open and under way.
- More trials run by University of Wisconsin, MadisonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Wisconsin, Madison
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Samuel Poore, MD, PhD, Principal investigator, University of Wisconsin, Madison
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04781907
- Sponsor's protocol ID
- 2020-1704
- Other IDs
- A539730, SMPH/SURGERY/DENTL-PLASTC SRGY, UW20171, Protocol Version 2/25/2021
- Status last verified
- May 2024
- First submitted
- 1 Mar 2021
- Last updated
- 28 May 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient Performed Tissue Expansion for Two-stage Alloplastic Breast Reconstruction
- ClinicalTrials.gov ID
- NCT04781907
- Acronym / sponsor ID
- 2020-1704
- Conditions
- Tissue Expansion, Breast Reconstruction
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Change in Research Priorities
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of Wisconsin, MadisonUniversity, hospital or other
- Study start
- Jun 2024 (estimated)
- Primary completion
- Jun 2025 (estimated)
- Study completion
- Jun 2025 (estimated)
- First posted
- 4 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to evaluate the feasibility and safety of patient performed tissue expansions in two-stage alloplastic breast reconstruction with tissue expanders. The investigators hypothesize that a motivated patient who learns and demonstrates proper technique can safely perform tissue expansions at home, with no increase in complications or problems with reconstruction. 30 participants will be recruited for this study, 10 into a Home Expansion Group, and 20 into a Control Group.
Detailed description
Two-stage tissue expander-to-implant reconstruction is the most common technique for breast reconstruction in the United States. Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants. The current clinical standard of care entails an initial surgery for the placement of tissue expander device either in front or behind of the pectoralis muscle following a mastectomy. After an interval of a few weeks to allow surgical wound healing, the patient will make serial office visits (usually weekly) where the plastic surgeon or other clinical staff will inject the device with a bolus of saline. A probe is used to find the magnetic port embedded in the expander, which is then accessed with a sterile butterfly needle connected to a large syringe filled with saline. The serial injections continue until the tissue expander(s) have reached the desired size. The patient then undergoes a second surgery about 4-6 weeks after the last injection, to exchange the tissue expander with a breast implant.
The tissue expansion process can be inconvenient for the patient, due to the time and cost associated with travel and coordination of frequent office visits. The office visits for tissue expander injections ultimately result with multiple additional encounters with a healthcare facility, which may be of concern to patients, in light of the COVID-19 pandemic.
The saline tissue expander with internal filling port is still the clinical gold standard device for alloplastic breast reconstruction. But the safety, time benefits and healthcare utilization and cost savings of home inflation - as shown in studies using external filling port tissue expanders and carbon dioxide-filled tissue expanders - suggests that patient performed tissue expansions may also be feasible with conventional saline tissue expanders. This would obviate multiple outpatient visits usually required for saline injections. Eliminating the need for saline injection clinic visits would benefit both the clinician and patient/families by reducing financial and time burdens, and limit potential exposures to COVID-19.
Study Design:
Ten women age 18 or above who met the inclusion and exclusion criteria below will be recruited and enrolled in the study. Study participants will be recruited from the principal investigator's clinic. Surgical technique and timing for initiation of expansion and implant exchange will be performed according to the principal investigator's usual protocol with saline tissue expanders. At the first expansion clinic visit, the saline injection will be performed by clinic staff, as per usual protocol. Clinic staff will provide teaching on the saline injection technique during this visit. At the second and third clinic visit, the participant will perform the saline injection under supervision by clinic staff in the right breast, the left breast will be expanded by the clinic staff. Starting the fourth expansion, participants will perform expansion in right breast prior to their clinic visit and left breast will be expanded by clinic staff. Thus participants will still be seen in person on a regular basis as per usual clinical protocol. If after the second and third visit the participant is unable to demonstrate ability and comfort to perform expansions on her own after the third clinic visit, she will be excluded from the study. Participants will be provided instructional materials and all supplies necessary to perform expansions at home. After the tissue expanders have been fully expanded, the participant will proceed to undergo the principal investigator's usual protocol of exchange to breast implants.
If at any time the participant has problem with home expansion or no longer wants to be part of the study, she can leave the study and receive all expansions in the clinic per usual protocol.
Objectives:
- 1. Evaluate overall treatment success in undergoing alloplastic breast reconstruction
- 2. Evaluate profile and rate of complications in patients performing tissue expansions at home
- 3. Compare treatment success and complication profile/rate of right (patient performed tissue expansion) and left (clinic performed tissue expansion) breast
- 4. Compare treatment success and complication profile/rate of patients who perform some tissue expansions at home vs patients who have all tissue expansions performed by clinical staff
- 5. Evaluate patient's satisfaction in experience of learning and performing expansions at home
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Home Expansion Group | Experimental | Procedure: Tissue ExpansionParticipants in home expansion group will perform the saline injection for their right tissue expander under clinic staff supervision on their 2nd and 3rd expansion. Beginning their 4th expansion, participants will perform saline injection at home prior to their regularly scheduled clinic visit. |
| Control Group | No intervention | –Standard of Care |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Undergoing two stage bilateral alloplastic breast reconstruction with tissue expander (either immediate or delayed)
- Able and willing to present for clinic visits every 1-2 weeks per tissue expansion protocol
- Physical, perceptual and cognitive capacity to understand, learn, perform and manage at-home expansions
- Provision of signed and dated informed consent form
Key exclusion criteria (12 listed)
- Failure to demonstrate proper tissue expander saline infiltration technique after two teachings and observations by clinic staff
- Tissue integrity unsuitable for tissue expansion (compromised vascularity, history of compromised wound healing, mastectomy skin flaps of questionable viability, excessively tight skin envelope)
- Residual gross tumor at intended expansion site
- Current or prior infection at intended expansion site
- Clinically significant fibrosis caused by previous irradiation or planned radiation therapy at intended expansion site during time expander is implanted
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tissue ExpansionTissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants. | Procedure or surgery | Home Expansion Group |
Primary outcome
Percent of Participants who had their breast tissue expanders successfully exchanged from expander to implant
Time frame: up to 6 months
Clinically, the tissue expander is only temporary and the main goal is to get patient to their permanent breast implant
Incidence of Adverse Events
Time frame: up to 6 months
Adverse events including - wound dehiscence, seroma, hematoma, extrusion, capsular contracture
2 secondary outcomes
Number of Right and Left breast tissue expanders successfully exchanged from expander to implant
Time frame: up to 6 months
Incidence of Adverse Events in Left vs Right Breast Tissue Expansion
Time frame: up to 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2024.
- Individual participant dataSharing planned: No
Related trials for Tissue Expansion
Recruiting
Blossom® Smart Expander Device for Tissue Expander/Implant-Based Breast Reconstruction
Tissue Expansion, Implant Based Breast Reconstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Samuel Poore, MD, PhD principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tissue Expansion in people with Tissue Expansion and Breast Reconstruction, run by University of Wisconsin, Madison at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 28 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent of Participants who had their breast tissue expanders successfully exchanged from expander to implant (time frame: up to 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2024; AzTrials last refreshed its copy on 7 Nov 2026.